The trajectory of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial release generated significant returns, the expiration of its patent opened the floodgates to off-brand versions, dramatically reducing revenue. This poses a particular risk for firms depending on related blockbuster pro

The legacy of Viagra, and its creator copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in revenue , its intellectual property lapse created a deluge of lower-priced alternatives , significantly diminishing its dominance. While certain firms may attempt to capitalize on male sexual dysfun